For more than a decade now, the global landscape of immuno-oncology (IO) clinical trials has been dominated by studies testing PD1 and PDL1 inhibitors, whether as monotherapy or in combinations. However, in 2022 that trend started to change. In this analysis, the Cancer Research Institute (CRI) provides its latest assessment on the global IO landscape, including year-by-year comparisons on therapy modalities, targets, and indications addressed in trials starting between 2018 and 2022.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Competing Interests
The authors declare no competing interests.